# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600.
B. Riley Securities analyst Mayank Mamtani maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target fr...
Goldman Sachs analyst Corinne Jenkins maintains TG Therapeutics (NASDAQ:TGTX) with a Neutral and raises the price target fro...
HC Wainwright & Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $49 price tar...